Product Description
Milnacipran is used to treat fibromyalgia (a long-lasting condition that may cause pain, muscle stiffness and tenderness, tiredness, and difficulty falling asleep or staying asleep). Milnacipran is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). It works by increasing the amount of serotonin and norepinephrine, natural substances that help stop the movement of pain signals in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a609016.html)
Mechanisms of Action: SRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Chile | Colombia | Dominican Republic | European Medicines Agency | Finland | France | Germany | India | Israel | Korea | Morocco | Peru | Portugal | Russia | Taiwan | Thailand | Turkey | United Kingdom | United States | Vietnam
Approved Indications: Fibromyalgia | Myalgia
Known Adverse Events: Hypertension | Dizziness | Headache | Hyperhidrosis | Constipation
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|